
SBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.
The Teva Biosimilars Trend Report: Perspectives from Managed Care, Providers & Employers.
Second edition.
Read the full report below: